Generation of a human induced pluripotent stem cell line (VRFi001-A) from orbital adipose tissue of a bilateral retinoblastoma patient with heterozygous RB1 gene deletion.
Vincent A., Khetan V., Rishi P., Suganeswari G., Krishnakumar S., Krishnan UM.
Laboratory Study, published in Stem Cell Res (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Stem Cell Res (2018)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 29579639
- DOI
- 10.1016/j.scr.2018.03.012
Abstract (original English)
Retinoblastoma (RB) is a pediatric intraocular tumor caused by mutations in retinoblastoma (RB1) gene. We have generated induced pluripotent stem cell line VRFi001-A from a bilateral retinoblastoma patient with heterozygous RB1 gene deletion. The iPSC line VRFi001-A retained the mutation and expressed pluripotency markers, had a normal karyotype and was capable of trilineage differentiation.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.